Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Journey Medical (DERM) EBIT (2020 - 2025)

Historic EBIT for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to -$1.5 million.

  • Journey Medical's EBIT rose 4716.66% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year increase of 6949.76%. This contributed to the annual value of -$13.7 million for FY2024, which is 55976.85% down from last year.
  • According to the latest figures from Q3 2025, Journey Medical's EBIT is -$1.5 million, which was up 4716.66% from -$2.9 million recorded in Q2 2025.
  • Journey Medical's EBIT's 5-year high stood at $17.2 million during Q3 2023, with a 5-year trough of -$13.8 million in Q2 2021.
  • In the last 5 years, Journey Medical's EBIT had a median value of -$3.3 million in 2025 and averaged -$4.5 million.
  • In the last 5 years, Journey Medical's EBIT crashed by 539121.34% in 2021 and then skyrocketed by 28167.93% in 2023.
  • Journey Medical's EBIT (Quarter) stood at -$9.1 million in 2021, then dropped by 10.36% to -$10.0 million in 2022, then surged by 78.95% to -$2.1 million in 2023, then soared by 206.18% to $2.2 million in 2024, then crashed by 168.44% to -$1.5 million in 2025.
  • Its EBIT was -$1.5 million in Q3 2025, compared to -$2.9 million in Q2 2025 and -$3.3 million in Q1 2025.